• Daiichi Sankyo Inc., of Parsippany, N.J., filed a supplemental new drug application for WelChol (colesevelam HCl) to improve glycemic control in patients with Type II diabetes mellitus. The drug was approved in 2000 for lowering LDL cholesterol. Sankyo has U.S. marketing rights to WelChol in a partnership with Cambridge, Mass.-based Genzyme Corp.

• Resverlogix Corp., of Calgary, Alberta, agreed to sell and issue $15 million in aggregate principal amount of subordinated convertible promissory notes, which are convertible into an aggregate of about 1.4 million shares of the company's common stock and accompanying warrants to purchase about 361,000 shares. Oppenheimer & Co. Inc. acted as placement agent and Caris & Co. acted as co-agent. Resverlogix focuses on developing therapies for cardiovascular disease.

• Rosetta Biosoftware, of Seattle, said Tokyo-based Eisai Co. Ltd. licensed its Elucidator system for differential protein expression analysis and biomarker discovery. Eisai will be using the system in the Laboratory of Seeds Finding Technology to support LC-MS quantification methods for identifying potential neurology biomarkers. Financial terms were not disclosed.